Compugen Price to Book Ratio 2006-2021 | CGEN

Historical price to book ratio values for Compugen (CGEN) over the last 10 years. The current price to book ratio for Compugen as of October 22, 2021 is 4.06.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Compugen Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 6.14 4.98
2021-06-30 8.28 $1.23 6.72
2021-03-31 8.59 0.00
2020-12-31 12.11 $1.43 8.46
2020-09-30 16.25 0.00
2020-06-30 15.02 $1.57 9.59
2020-03-31 7.26 0.00
2019-12-31 5.96 $0.56 10.56
2019-09-30 4.23 0.00
2019-06-30 3.84 $0.51 7.48
2019-03-31 4.14 0.00
2018-12-31 2.17 $0.62 3.49
2018-09-30 3.85 0.00
2018-06-30 3.30 $0.71 4.66
2018-03-31 4.45 0.00
2017-12-31 2.50 $0.57 4.38
2017-09-30 3.80 0.00
2017-06-30 3.80 $0.92 4.11
2017-03-31 4.30 0.00
2016-12-31 5.10 $1.24 4.11
2016-09-30 6.30 0.00
2016-06-30 6.48 0.00
2016-03-31 5.58 0.00
2015-12-31 6.39 $1.78 3.59
2015-09-30 5.17 0.00
2015-06-30 6.94 0.00
2015-03-31 7.05 0.00
2014-12-31 8.33 $2.11 3.94
2014-09-30 8.57 0.00
2014-06-30 8.99 0.00
2014-03-31 10.51 0.00
2013-12-31 8.95 0.00
2013-09-30 10.26 0.00
2013-06-30 5.43 0.00
2013-03-31 5.07 0.00
2012-12-31 4.92 0.00
2012-09-30 3.76 0.00
2012-06-30 3.86 0.00
2012-03-31 5.99 0.00
2011-12-31 4.95 0.00
2011-09-30 4.00 0.00
2011-06-30 4.06 0.00
2011-03-31 5.14 0.00
2010-12-31 4.92 0.00
2010-09-30 4.72 0.00
2010-06-30 3.33 0.00
2010-03-31 4.90 0.00
2009-12-31 4.85 0.00
2009-09-30 3.06 0.00
2009-06-30 2.01 0.00
2009-03-31 0.66 0.00
2008-12-31 0.43 0.00
2008-09-30 1.66 0.00
2008-06-30 2.15 0.00
2008-03-31 2.09 0.00
2007-12-31 1.60 0.00
2007-09-30 2.49 0.00
2007-06-30 2.91 0.00
2007-03-31 2.66 0.00
2006-12-31 2.59 0.00
2006-09-30 2.86 0.00
2006-06-30 2.89 0.00
2006-03-31 3.85 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.420B $0.002B
Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76